IFIH1 and dermatomyositis: Besides, a Japanese cohort study demonstrates no survival benefit of initial triple therapy over bitherapy or monotherapy on different anti‐MDA5 DM clusters, warranting the evaluation of alternative therapeutic strategies [16].